Monoclonal Antibody Guided Radiotherapy for Ovarian Cancer
Author Information
Author(s): B. Ward, S. Mather, J. Shepherd, M. Crowther, L. Hawkins, K. Britton, M.L. Slevin
Primary Institution: Imperial Cancer Research Fund, London; St. Bartholomew's Hospital and Homerton Hospitals, London, UK
Hypothesis
Can intraperitoneal monoclonal antibody guided radiotherapy effectively treat ovarian carcinoma and control malignant ascites?
Conclusion
The study suggests that while there is no therapeutic benefit for solid intraperitoneal tumors, the treatment may help control malignant ascites in some patients.
Supporting Evidence
- Three patients with recurrent malignant ascites had their condition controlled for a mean of 4 months.
- One patient showed disappearance of tumor cells from ascitic fluid after therapy.
- Three of four assessable patients with malignant ascites had resolution of their ascites.
Takeaway
Doctors tried a new treatment for ovarian cancer using special antibodies and radiation, but it didn't work well for tumors, though it helped some patients with fluid buildup in their bellies.
Methodology
Patients with ovarian cancer and recurrent malignant ascites were treated with intraperitoneal monoclonal antibody guided radiotherapy and evaluated for response after three months.
Limitations
The study had a small sample size and did not demonstrate overall regression of disease in solid tumors.
Participant Demographics
Patients included those with small volume ovarian carcinoma and recurrent malignant ascites, with varied previous treatments.
Want to read the original?
Access the complete publication on the publisher's website